These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32542213)

  • 1. Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review.
    Barrett CD; Moore HB; Moore EE; McIntyre RC; Moore PK; Burke J; Hua F; Apgar J; Talmor DS; Sauaia A; Liptzin DR; Veress LA; Yaffe MB
    Res Pract Thromb Haemost; 2020 May; 4(4):524-531. PubMed ID: 32542213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.
    Wang J; Hajizadeh N; Moore EE; McIntyre RC; Moore PK; Veress LA; Yaffe MB; Moore HB; Barrett CD
    J Thromb Haemost; 2020 Jul; 18(7):1752-1755. PubMed ID: 32267998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
    Whyte CS; Morrow GB; Mitchell JL; Chowdary P; Mutch NJ
    J Thromb Haemost; 2020 Jul; 18(7):1548-1555. PubMed ID: 32329246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study.
    Corey KM; Olson LB; Naqvi IA; Morrison SA; Davis C; Nimjee SM; Que LG; Bachelder RE; Kraft BD; Chen L; Nair SK; Levy JH; Sullenger BA
    Anesthesiology; 2022 Jul; 137(1):67-78. PubMed ID: 35412597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
    Miesbach W; Makris M
    Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboelastography to Detect Hypercoagulability and Reduced Fibrinolysis in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome Patients.
    Sadd C; Rowe T; Nazeef M; Kory P; Sultan S; Faust H
    Crit Care Explor; 2020 Sep; 2(9):e0192. PubMed ID: 32984828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series.
    Barrett CD; Oren-Grinberg A; Chao E; Moraco AH; Martin MJ; Reddy SH; Ilg AM; Jhunjhunwala R; Uribe M; Moore HB; Moore EE; Baedorf-Kassis EN; Krajewski ML; Talmor DS; Shaefi S; Yaffe MB
    J Trauma Acute Care Surg; 2020 Sep; 89(3):453-457. PubMed ID: 32427773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 coagulopathy - what should we treat?
    Chowdary P
    Exp Physiol; 2022 Jul; 107(7):749-758. PubMed ID: 35733235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach.
    García-Ortega A; de la Rosa D; Oscullo G; Castillo-Villegas D; López-Reyes R; Martínez-García MÁ
    J Thorac Dis; 2021 Feb; 13(2):1239-1255. PubMed ID: 33717596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome.
    Ware LB; Matthay MA; Parsons PE; Thompson BT; Januzzi JL; Eisner MD;
    Crit Care Med; 2007 Aug; 35(8):1821-8. PubMed ID: 17667242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of Coagulopathy in Hematological Malignancies and in COVID-19.
    Levi M
    Hemasphere; 2021 Jun; 5(6):e571. PubMed ID: 34095755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.
    Choudhury R; Barrett CD; Moore HB; Moore EE; McIntyre RC; Moore PK; Talmor DS; Nydam TL; Yaffe MB
    World J Emerg Surg; 2020 Apr; 15(1):29. PubMed ID: 32312290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.
    Nougier C; Benoit R; Simon M; Desmurs-Clavel H; Marcotte G; Argaud L; David JS; Bonnet A; Negrier C; Dargaud Y
    J Thromb Haemost; 2020 Sep; 18(9):2215-2219. PubMed ID: 32668058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.
    Papamichalis P; Papadogoulas A; Katsiafylloudis P; Skoura AL; Papamichalis M; Neou E; Papadopoulos D; Karagiannis S; Zafeiridis T; Babalis D; Komnos A
    Int J Infect Dis; 2020 Aug; 97():90-93. PubMed ID: 32497796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.
    Ortega-Paz L; Capodanno D; Montalescot G; Angiolillo DJ
    J Am Heart Assoc; 2021 Feb; 10(3):e019650. PubMed ID: 33228447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19.
    Bahraini M; Dorgalaleh A
    Semin Thromb Hemost; 2022 Feb; 48(1):19-30. PubMed ID: 34695858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19, coagulopathy and venous thromboembolism: more questions than answers.
    Marietta M; Coluccio V; Luppi M
    Intern Emerg Med; 2020 Nov; 15(8):1375-1387. PubMed ID: 32653981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.